专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070129346A1 Melanocortin receptor agonists 失效
标题翻译：黑皮质素受体激动剂
公开(公告)号：US20070129346A1
公开(公告)日：2007-06-07
申请号：US10579042
申请日：2004-11-12
申请人： Koo Lee , Heui-Sul Park , In-Ae Ahn , Hyun-Ju Yoo , Jong-Yup Kim , Deog-Young Choi , Hyeon-Joo Yim , Kyung-Ha Chung , Dong-Sup Shim , Sang-Kyun Lee , Yutaka Kondoh , Ryoji Hirabayashi , Shugo Honda , Hidetaka Kaku , Jun-ichi Shishikura , Hiroyuki Ito , Takeshi Kurama
发明人： Koo Lee , Heui-Sul Park , In-Ae Ahn , Hyun-Ju Yoo , Jong-Yup Kim , Deog-Young Choi , Hyeon-Joo Yim , Kyung-Ha Chung , Dong-Sup Shim , Sang-Kyun Lee , Yutaka Kondoh , Ryoji Hirabayashi , Shugo Honda , Hidetaka Kaku , Jun-ichi Shishikura , Hiroyuki Ito , Takeshi Kurama
IPC分类号： A61K31/397 , A61K31/401 , A61K31/445 , C07D211/06
CPC分类号： C04B35/632 , C07D205/04 , C07D207/14 , C07D211/58 , C07D401/12 , C07D403/12 , C07D405/12
摘要： The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.
摘要翻译：本发明涉及有效作为黑皮质素受体激动剂的式1化合物及其药学上可接受的盐，水合物，溶剂化物或异构体，以及包含与活性成分相同的黑皮质素受体激动剂组合物。

2. 发明申请

US20060276545A1 Polyhydroxy phenols and their use in binding p-selectin 失效
标题翻译：多羟基酚及其在结合p-选择素中的应用
公开(公告)号：US20060276545A1
公开(公告)日：2006-12-07
申请号：US10558495
申请日：2004-05-07
申请人： Erik Anna Biessen , Chantal Appeldoorn , Arnaud Bonnefoy , Theodorus Van Berkel , Johan Kuiper , Marc Hoylaerts
发明人： Erik Anna Biessen , Chantal Appeldoorn , Arnaud Bonnefoy , Theodorus Van Berkel , Johan Kuiper , Marc Hoylaerts
IPC分类号： A61K31/198 , C07C237/02
CPC分类号： C07D209/20 , A61K9/107 , A61K9/127 , C07C69/96 , C07C237/22
摘要： Polyhydroxy phenols, which are non-peptidic mimetics of galloyl peptides, and a process for the preparation of gallic acid derivatives using a gallic-acid providing moiety are provided as well as polyhydroxy phenol-containing pharmaceutical and nutraceutical compositions. The use of polyhydroxy phenols as a medicament and especially for the manufacture of a medicament for the prevention, treatment or diagnosis of a disease or a condition, wherein P-selectin is involved, is provided. The same compounds can also be used as targeting tools to P-selectin expressing cells or tissues in a composition, further comprising an active compound in a vehicle.
摘要翻译：提供作为酰基肽的非肽模拟物的多羟基酚，以及使用没食子酸提供部分制备没食子酸衍生物的方法以及含有多羟基苯酚的药物和营养组合物。提供了使用多羟基酚作为药物，特别是制备用于预防，治疗或诊断其中涉及P-选择素的疾病或病症的药物。相同的化合物也可以用作组合物中表达P-选择蛋白的细胞或组织的靶向工具，还包含载体中的活性化合物。

3. 发明申请

US20050233304A1 Method of screening remedy for renal failure 审中-公开
标题翻译：筛查肾功能衰竭的方法
公开(公告)号：US20050233304A1
公开(公告)日：2005-10-20
申请号：US10516517
申请日：2003-10-09
申请人： Kentaro Enjo , Sadao Kuromitsu
发明人： Kentaro Enjo , Sadao Kuromitsu
IPC分类号： A61K38/00 , A61P13/12 , C07K14/705 , C12N15/12 , G01N33/68 , C12Q1/00 , A61K38/18
CPC分类号： G01N33/6893 , A61K38/00 , C07K14/705 , G01N2500/00
摘要： A screening tool and a convenient screening method for obtaining a renal failure treating agent, and a pharmaceutical composition for treating renal failure and a production method thereof are disclosed. The aforementioned screening tool is a G protein coupling type receptor FGK which is a polypeptide capable of activating CTGF promoter, a functionally equivalent modified substance thereof or a homologous polypeptide, or a cell expressing the aforementioned polypeptide. The screening method is a method which employs inhibition of the aforementioned polypeptide as the index.
摘要翻译：公开了筛选工具和用于获得肾衰竭治疗剂的方便的筛选方法，以及用于治疗肾衰竭的药物组合物及其制备方法。上述筛选工具是G蛋白偶联型受体FGK，其是能够激活CTGF启动子，其功能等同的修饰物质或同源多肽或表达上述多肽的细胞的多肽。筛选方法是采用上述多肽的抑制作为指标的方法。

4. 发明授权

US06903125B2 Tetrahydro-2H-thiopyran-4-carboxamide derivative 有权
标题翻译：四氢-2H-噻喃-4-甲酰胺衍生物
公开(公告)号：US06903125B2
公开(公告)日：2005-06-07
申请号：US10912232
申请日：2004-08-06
申请人： Toru Kontani , Junji Miyata , Wataru Hamaguchi , Tomoaki Kawano , Akio Kamikawa , Hiroshi Suzuki , Kenji Sudo
发明人： Toru Kontani , Junji Miyata , Wataru Hamaguchi , Tomoaki Kawano , Akio Kamikawa , Hiroshi Suzuki , Kenji Sudo
IPC分类号： A61P31/22 , C07D335/02 , C07D413/12 , A61K31/41 , C07D271/06
CPC分类号： C07D335/02 , C07D413/12
摘要： A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.
摘要翻译：一种药物，特别是可用于预防或治疗涉及疱疹病毒科家族病毒感染的各种疾病的新型化合物，特别是各种疱疹病毒感染如通过水痘带状疱疹病毒的水痘（水痘），水痘带状疱疹通过潜在的复发性感染水痘带状疱疹病毒，通过HSV-1和生殖器疱疹通过HSV-2感染的唇疱疹和疱疹脑炎。 N- {2 - [（4-取代的苯基）氨基] -2-氧代乙基}四氢-2H-噻喃-4-甲酰胺衍生物，其中苯基在4位被特定的5元或6元杂芳基取代具有如此巨大的抗病毒活性，以低剂量的口服给药能够治疗疾病。

5. 发明申请

US20050100607A1 Method for improving adsorption of a drug from ethylene oxide derivative 失效
标题翻译：改善环氧乙烷衍生物吸收药物的方法
公开(公告)号：US20050100607A1
公开(公告)日：2005-05-12
申请号：US10672398
申请日：2003-09-26
申请人： Keiichi Yoshihara , Kazuhiro Sako
发明人： Keiichi Yoshihara , Kazuhiro Sako
IPC分类号： A61K9/00 , A61K9/14 , A61K47/10 , A61K47/32 , A61P31/04 , A61P43/00
CPC分类号： A61K47/10 , A61K9/0065
摘要： The present invention relates to a method for improving adsorption on the gastrointestinal mucous layers of one or more selected from polyethylene glycol, polyethylene oxide, and polyoxyethylene polypropylene copolymer wherein the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater. It is possible to enhance pharmacological effects by using the present invention with drugs that have anti-H. pylori activity.
摘要翻译：本发明涉及一种改善一个或多个选自聚乙二醇，聚环氧乙烷和聚氧乙烯聚丙烯共聚物中的一种或多种吸附的方法，其中一个环氧乙烷链长度的重复氧化乙烯单元的平均数为17或更大。本发明可以通过具有抗-H的药物来提高药理作用。幽门螺杆菌活动。

6. 发明申请

US20050100598A1 Quick disintegrating tablet in buccal cavity and production process thereof 审中-公开
标题翻译：颊腔快速崩解片及其制作方法
公开(公告)号：US20050100598A1
公开(公告)日：2005-05-12
申请号：US10961875
申请日：2004-10-07
申请人： Takao Mizumoto , Yoshinori Masuda , Atsushi Kajiyama , Masahiro Yanagisawa , Janaki Ram Nyshadham
发明人： Takao Mizumoto , Yoshinori Masuda , Atsushi Kajiyama , Masahiro Yanagisawa , Janaki Ram Nyshadham
IPC分类号： A61K9/00 , A61K9/20 , A61K47/26 , A61K47/36 , H04L12/44 , H04L29/06 , H04L29/08
CPC分类号： H04L12/44 , A61K9/0056 , A61K9/2018 , A61K9/2095 , H04L29/06 , H04L67/12 , H04L67/26 , H04L69/08 , H04L69/329
摘要： The present invention relates to a quick disintegrating tablet in buccal cavity, comprising: a mixture, comprising a drug, a sugar (A), and an amorphous sugar (B), and after it is forming a tablet, it is humidified and dried. In particularly, the present invention relates to a quick disintegrating tablet in buccal cavity comprising: a mixture; comprising a drug, a sugar (A), and an amorphous sugar (B) which an amorphous-forming sugar in crystalline state is dissolved in a medicinally permitted solvent, the amorphous sugar is obtained from this solution by removing the solvent, and after it is forming a tablet, and it is humidified and dried. The tablet in the present invention is to provide stability against moisture at preserved, because the amorphous sugar changed to the crystalline state in a nonreversible reaction after it is humidified and dried in a manufacturing process. The tablet in the present invention is to further provide a design for the pharmaceutical preparation with respect to the stability of a drug, because the tablet is manufactured by one kind of a sugar and an amorphous sugar. Furthermore, the tablet in the present invention is to provide a production process by utilizing a common granulating machine and by utilizing a common tablet machine.
摘要翻译：本发明涉及颊腔中的快速崩解片，其包含：包含药物，糖（A）和无定形糖（B）的混合物，在形成片剂之后，将其加湿干燥。特别地，本发明涉及颊腔中的快速崩解片剂，其包含：混合物; 包含药物，糖（A）和无定形糖（B），其中结晶状态的无定形形成糖溶解在药物允许溶剂中，通过除去溶剂从该溶液获得无定形糖，之后正在形成片剂，并且被加湿和干燥。本发明中的片剂是为了提供在保存的水分中的稳定性，因为无定形糖在制造过程中被加湿干燥后，在不可逆反应中变为结晶状态。本发明的片剂是为了进一步提供关于药物的稳定性的药物制剂的设计，因为片剂由一种糖和无定形糖制造。此外，本发明中的片剂是通过利用普通的造粒机和利用普通的压片机来提供制造方法。

7. 发明授权

US06878525B1 Peptide leukotriene receptor 有权
标题翻译：肽白三烯受体
公开(公告)号：US06878525B1
公开(公告)日：2005-04-12
申请号：US09979603
申请日：2000-09-13
申请人： Jun Takasaki , Masazumi Kamohara , Mitsuyuki Matsumoto , Tetsu Saito , Tohru Sugimoto , Toshio Ota , Takao Isogai , Tetsuo Nishikawa , Yuri Kawai
发明人： Jun Takasaki , Masazumi Kamohara , Mitsuyuki Matsumoto , Tetsu Saito , Tohru Sugimoto , Toshio Ota , Takao Isogai , Tetsuo Nishikawa , Yuri Kawai
IPC分类号： A61K38/00 , A61P9/08 , A61P43/00 , C07K14/705 , C12N15/12 , G01N33/68 , G01N33/567
CPC分类号： C07K14/705 , A61K38/00 , G01N33/6893 , G01N2500/00 , G01N2500/04
摘要： A cDNA encoding a novel LTC4 receptor has been isolated. Provision of the novel protein, an LTC4 receptor, enabled binding experiments using the LTC4. By screening for compounds that modulate LTC4 receptor activity based on these binding experiments, development of drugs targeting the LTC4 receptor becomes possible.
摘要翻译：已经分离出编码新的LTC4受体的cDNA。提供新的蛋白质LTC4受体，启用使用LTC4的结合实验。通过筛选基于这些结合实验调节LTC4受体活性的化合物，开发靶向LTC4受体的药物成为可能。

8. 发明申请

US20050031587A1 Immune response induction method 审中-公开
标题翻译：免疫反应诱导方法
公开(公告)号：US20050031587A1
公开(公告)日：2005-02-10
申请号：US10674581
申请日：2003-09-29
申请人： Yuuki Tsutsui , Kiyo Nakanishi , Shunsuke Watanabe , Shigeo Takemura
发明人： Yuuki Tsutsui , Kiyo Nakanishi , Shunsuke Watanabe , Shigeo Takemura
IPC分类号： A61K38/21 , A61K39/00
CPC分类号： A61K39/39 , A61K38/212 , A61K2039/543 , A61K2039/55522 , A61K2300/00
摘要： The present invention proposes a method of inducing both vaccine antigen-specific antibody in blood and vaccine antigen-specific antibody secreted at the mucosal surface using vaccine antigen and adjuvant of said vaccine antigen.
摘要翻译：本发明提出了使用疫苗抗原和所述疫苗抗原的佐剂诱导血液中的疫苗抗原特异性抗体和分泌在粘膜表面的疫苗抗原特异性抗体的方法。

9. 发明申请

US20040253309A1 Enteric sustained-release fine particles of tamsulosin and its salt and manufacturing method thereof 审中-公开
标题翻译：肠溶缓慢释放的坦索罗辛缓释微粒及其盐及其制备方法
公开(公告)号：US20040253309A1
公开(公告)日：2004-12-16
申请号：US10766201
申请日：2004-01-27
申请人： Yamanouchi Pharmaceutical Co., Ltd.
发明人： Yoji Tanijiri , Akira Ito , Hiroya Sugao , Tetsuya Tamura , Mare Nishura , Shigeru Yamazaki , Takao Mizumoto
IPC分类号： A61K009/26
CPC分类号： A61K9/0056 , A61K9/1652 , A61K9/5026 , A61K31/18
摘要： The present invention relates to enteric sustained-release fine particles of tamsulosin or its salt that can be contained in tablets that disintegrate in the buccal cavity and a manufacturing method thereof. In further detail, the present invention relates to enteric sustained-release fine particles for tablets that disintegrate in the buccal cavity, which comprise (1) tamsulosin or its salt and at least (2) an enterosoluble substance, and when necessary contain (3) a water-insoluble substance, and which have the following characteristics: 1) a particle diameter of approximately 5 to 250 nullm 2) when dissolution tests are performed on tablets that disintegrate in the buccal cavity containing these particles by dissolution testing methods cited in the Japanese Pharmacopoeia, a) the dissolution rate of tamsulosin or its salt at a pH of 1.2 two hours after starting tests is 25% or less b) the time when 50% of the tamsulosin or its salt has dissolved at a pH of 6.8 is 0.5 to 5 hours, and a manufacturing method thereof.
摘要翻译：本发明涉及可以包含在颊腔中分解的片剂中的坦索罗辛或其盐的肠溶缓释微粒及其制造方法。更详细地说，本发明涉及在颊腔中崩解的片剂的肠溶缓释微粒，其包含（1）坦洛新或其盐和至少（2）肠溶性物质，并且在必要时包含（3）一种水不溶性物质，具有以下特征：1）粒径约5〜250μm2）当对含有这些颗粒的颊腔分解的片剂进行溶解试验时，通过日本的溶出试验方法药典，a）在开始试验后两小时pH2.2时，坦索罗辛或其盐的溶解速率为25％以下b）当pH值为6.8时，坦索罗辛或其盐50％溶解的时间为0.5〜 5小时及其制造方法。

10. 发明申请

US20040068109A1 Diazepan derivatives or salts thereof 有权
标题翻译：二氮杂环庚烷衍生物或其盐
公开(公告)号：US20040068109A1
公开(公告)日：2004-04-08
申请号：US10656129
申请日：2003-09-08
申请人： YAMANOUCHI PHARMACEUTICAL CO. LTD.
发明人： Fukushi Hirayama , Hiroyuki Koshio , Tsukasa Ishihara , Norio Seki , Shunichiro Hachiya , Keizo Sugasawa , Ryota Shiraki , Yuji Koga , Yuzo Matsumoto , Takeshi Shigenaga , Souichirou Kawazoe
IPC分类号： A61K031/551 , C07D243/08
CPC分类号： C07D401/04 , A61K31/551 , C07D243/08 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/04 , C07D409/12 , C07D471/04
摘要： To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-null(3-carbamimidoylphenylamino)methylnull-3-null4-(4-methyl-1,4-diazepan-1-yl)benzoylaminonullbenzoic acid and 3-hydroxy-4null-methoxy-2-nullnull4-(4-methyl-1,4-diazepan-1-yl)benzoylnullaminonullbenzanilide or a salt thereof is an effective ingredient.
摘要翻译：提供具有基于活化凝血因子X的抑制的抗凝作用的化合物，并且可用作抗凝血剂或用于预防和治疗由血栓或栓塞引起的疾病的药剂。二氮杂环丁烷衍生物如4 - [（3-氨甲酰氨基）甲基] -3- [4-（4-甲基-1,4-二氮杂环庚烷-1-基）苯甲酰基氨基]苯甲酸和3-羟基-4'-甲氧基 - 2 - {[4-（4-甲基-1,4-二氮杂环庚烷-1-基）苯甲酰基]氨基} -N-苯甲酰苯胺或其盐是有效成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式